Millennium Management LLC Has $85.17 Million Stake in Abiomed (NASDAQ:ABMD)

Millennium Management LLC increased its stake in shares of Abiomed (NASDAQ:ABMD) by 20.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 454,439 shares of the medical equipment provider’s stock after buying an additional 76,286 shares during the period. Millennium Management LLC owned about 1.03% of Abiomed worth $85,166,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Swiss National Bank increased its holdings in Abiomed by 2.4% during the fourth quarter. Swiss National Bank now owns 71,300 shares of the medical equipment provider’s stock worth $13,362,000 after buying an additional 1,700 shares during the last quarter. Pratt Collard Advisory Partners LLC purchased a new stake in Abiomed during the fourth quarter worth about $412,000. Hamilton Lane Advisors LLC increased its holdings in Abiomed by 50.8% during the fourth quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock worth $4,356,000 after buying an additional 7,827 shares during the last quarter. Janney Montgomery Scott LLC increased its holdings in Abiomed by 46.3% during the third quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock worth $489,000 after buying an additional 919 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. purchased a new stake in Abiomed during the third quarter worth about $1,530,000. Institutional investors and hedge funds own 88.42% of the company’s stock.

How to Become a New Pot Stock Millionaire

NASDAQ:ABMD traded down $5.91 on Friday, reaching $286.22. 335,208 shares of the company’s stock were exchanged, compared to its average volume of 410,975. The firm has a market capitalization of $12,673.25, a PE ratio of 244.63, a P/E/G ratio of 2.81 and a beta of 0.17. Abiomed has a 52 week low of $117.36 and a 52 week high of $304.28.

Abiomed (NASDAQ:ABMD) last issued its earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.20. Abiomed had a net margin of 16.58% and a return on equity of 15.54%. The firm had revenue of $154.00 million during the quarter, compared to analyst estimates of $154.00 million. During the same quarter last year, the business earned $0.34 earnings per share. The company’s quarterly revenue was up 34.9% on a year-over-year basis. sell-side analysts expect that Abiomed will post 2.29 EPS for the current year.

In other news, VP Andrew J. Greenfield sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total value of $5,407,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is currently owned by company insiders.

A number of analysts recently issued reports on ABMD shares. BidaskClub downgraded shares of Abiomed from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Jefferies Group raised their price objective on shares of Abiomed to $250.00 and gave the stock a “buy” rating in a report on Friday, January 12th. Goldman Sachs assumed coverage on shares of Abiomed in a research report on Wednesday. They set a “buy” rating and a $332.00 target price for the company. SunTrust Banks reiterated a “buy” rating and set a $370.00 target price on shares of Abiomed in a research report on Friday, February 16th. Finally, Leerink Swann increased their target price on shares of Abiomed to $300.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Two analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $309.50.

WARNING: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/millennium-management-llc-acquires-76286-shares-of-abiomed-inc-abmd.html.

About Abiomed

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump.

Institutional Ownership by Quarter for Abiomed (NASDAQ:ABMD)

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply